Quick Answer
Allogene Therapeutics, Inc. reported Total Assets of $415.91 million for the year ending 2025.
- Allogene Therapeutics, Inc. showed a decrease of -24.2% in Total Assets from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2018 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $435.24 million | Q1 2019: $749.37 million | Q2 2019: $734.00 million | Q3 2019: $695.54 million | Q1 2020: $688.52 million | Q2 2020: $1.26 billion | Q3 2020: $1.22 billion | Q1 2021: $1.18 billion | Q2 2021: $1.13 billion | Q3 2021: $1.08 billion | Q1 2024: $586.35 million | Q2 2024: $646.88 million | Q3 2024: $589.12 million | Q1 2025: $507.98 million | Q2 2025: $470.59 million | Q3 2025: $439.77 million.
- Over the full 14 years of available data (2018 to 2025), Allogene Therapeutics, Inc.'s Total Assets has declined by 46.3%.
- Historical annual values: Fiscal year 2025: $415.91 million | Fiscal year 2024: $548.71 million | Fiscal year 2023: $642.84 million | Fiscal year 2023: $713.41 million | Fiscal year 2023: $773.01 million | Fiscal year 2023: $750.13 million | Fiscal year 2022: $821.58 million | Fiscal year 2022: $894.48 million | Fiscal year 2022: $955.62 million | Fiscal year 2022: $978.09 million | Fiscal year 2021: $1.04 billion | Fiscal year 2020: $1.23 billion | Fiscal year 2019: $717.80 million | Fiscal year 2018: $773.86 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: